ES2962520T3 - Agentes quelantes bifuncionales - Google Patents

Agentes quelantes bifuncionales Download PDF

Info

Publication number
ES2962520T3
ES2962520T3 ES17200176T ES17200176T ES2962520T3 ES 2962520 T3 ES2962520 T3 ES 2962520T3 ES 17200176 T ES17200176 T ES 17200176T ES 17200176 T ES17200176 T ES 17200176T ES 2962520 T3 ES2962520 T3 ES 2962520T3
Authority
ES
Spain
Prior art keywords
nmr
mmol
mhz
dedpa
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17200176T
Other languages
English (en)
Spanish (es)
Inventor
Mike Adam
Eszter Boros
Cara Ferreira
Chris Orvig
Eric Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BWXT Medical Ltd
Original Assignee
BWXT Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BWXT Medical Ltd filed Critical BWXT Medical Ltd
Application granted granted Critical
Publication of ES2962520T3 publication Critical patent/ES2962520T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES17200176T 2010-02-19 2011-02-18 Agentes quelantes bifuncionales Active ES2962520T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30625610P 2010-02-19 2010-02-19
US39473910P 2010-10-19 2010-10-19

Publications (1)

Publication Number Publication Date
ES2962520T3 true ES2962520T3 (es) 2024-03-19

Family

ID=44482427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17200176T Active ES2962520T3 (es) 2010-02-19 2011-02-18 Agentes quelantes bifuncionales

Country Status (7)

Country Link
US (1) US8772446B2 (enExample)
EP (2) EP2536691B1 (enExample)
JP (1) JP5856982B2 (enExample)
DK (1) DK2536691T3 (enExample)
ES (1) ES2962520T3 (enExample)
NO (1) NO2536691T3 (enExample)
WO (1) WO2011100829A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075079A1 (en) * 2012-11-12 2014-05-15 The General Hospital Corporation Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
CN104152520B (zh) * 2014-07-30 2017-01-18 华南理工大学 一种具有抗肿瘤活性的核桃多肽‑锌螯合物的制备方法
CN108136053B (zh) * 2015-08-13 2022-05-27 通用医疗公司 用于mr分子成像的基于锰的螯合缀合物
CN106496110B (zh) * 2016-09-05 2019-04-23 郑州大学 金属β-内酰胺酶抑制剂开链吡啶羧酸衍生物及其制备方法
KR101851979B1 (ko) * 2017-03-23 2018-06-07 (주) 에프엔지리서치 중금속 및 포름알데히드 제거능을 가지는 세제 조성물
JP2024125438A (ja) * 2021-08-03 2024-09-19 住友化学株式会社 放射性金属錯体及びその製造方法、並びに放射性金属捕捉剤
CN116041257B (zh) * 2023-02-02 2024-10-15 杭州谱康医学科技有限公司 金属螯合配体及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021567A (en) * 1987-09-24 1991-06-04 Abbott Laboratories 8-hydroxyquinoline chelating agents
US5220000A (en) * 1992-01-23 1993-06-15 Spyros Theodoropulos Bifunctional-bis-quinolinols, and their metal chelates
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
FR2896501B1 (fr) 2006-01-20 2008-04-25 Commissariat Energie Atomique Nouveaux ligands et complexes de lanthanides, et leur utilisation en tant qu'agents de contraste

Also Published As

Publication number Publication date
JP2013519692A (ja) 2013-05-30
DK2536691T3 (en) 2018-02-19
NO2536691T3 (enExample) 2018-04-21
US20110313130A1 (en) 2011-12-22
WO2011100829A8 (en) 2011-10-27
US8772446B2 (en) 2014-07-08
EP2536691A1 (en) 2012-12-26
WO2011100829A1 (en) 2011-08-25
EP3318555A1 (en) 2018-05-09
EP3318555B1 (en) 2023-08-16
EP2536691A4 (en) 2013-08-14
EP3318555C0 (en) 2023-08-16
EP2536691B1 (en) 2017-11-22
JP5856982B2 (ja) 2016-02-10

Similar Documents

Publication Publication Date Title
ES2962520T3 (es) Agentes quelantes bifuncionales
Boros et al. RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga
AU2019225154B2 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
EP3417883B1 (en) Targeted alpha-particle emitting complexes comprising thorium radionuclide and hydroxypyridinone containing ligand
CA3215134A1 (en) Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US9061078B2 (en) Tetraaza macrocyclic compound, preparation method thereof and use thereof
JPH02501141A (ja) テトラ‐アザ大環状化合物およびその金属錯体
US10646598B2 (en) Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same
CN118955616B (zh) 一种靶向结合成纤维细胞活化蛋白化合物及应用
Hueting et al. Bis (thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides
ES2899860T3 (es) Nuevo compuesto que contiene nitrógeno o sal del mismo, o complejo de metal de los mismos
KR20240035488A (ko) 섬유아세포 활성화 단백질(fap)과 결합하는 방사성 트레이서들 및 치료제들
WO2013060793A1 (en) Bifunctional ligands for radiometals
Tzovas et al. Synthesis and biological evaluation of 99mTc-tricarbonyl complexes of C-3 carboxy derivatives of fluoroquinolones in infection and tumor animal models
US20120095185A1 (en) Process for chelating copper ions using cb-te2a bifunctional chelate
US20250215027A1 (en) Diphosphine compounds and complexes
HK40097471A (en) Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
HK40063347A (en) Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof